Dual‑platform Capabilities Empower Global Pharmaceutical Collaboration with Vibrant On‑site Exchanges
October 6, 2026, Milan, Italy — CPHI Worldwide 2026, the flagship global pharmaceutical industry event, officially opened at Fiera Milano. As a one‑stop C(D)MO service provider and API supplier, Sintaho showcased its dual technology platforms for peptides and small molecules and full‑life‑cycle service solutions at Booth 3K47, Hall 3. Sintaho engaged in in‑depth discussions with pharmaceutical enterprises, R&D institutions and industry partners worldwide to explore new opportunities for global pharmaceutical collaboration.
Dual‑platform Synergy Focusing on High‑value Tracks
At this year’s exhibition, Sintaho highlighted its integrated technology platform system built on peptide and small‑molecule platforms.
The peptide platform adopts dual‑mode SPPS/LPPS processes for linear peptides and sophisticated cyclic peptides. It delivers capabilities including side‑chain conjugation, cyclization strategies and compliance‑driven impurity profiling, achieving HPLC purity above 99.0 % and industry‑leading single‑impurity control. A 1,500 kg‑per‑annum peptide production line for GLP‑1 APIs is fully operational, catering to API supply for generic‑drug clients and CDMO partnerships for innovator‑drug developers. Aligned with FDA peptide impurity classification guidelines, Sintaho implements targeted removal of major impurities and conducts structural characterization or immunogenicity risk assessment for impurities exceeding reporting thresholds. These strengths drew extensive enquiries from innovator and generic pharmaceutical companies at the show.
The small‑molecule platform features an OEB5 high‑potency API production line focused on high‑potency APIs and XDC therapeutics. The facility supports commercial‑scale manufacturing of high‑potency compounds up to 50 kg, equipped with fully closed isolator systems to handle all high‑potency substances. The platform excels in chiral synthesis, genotoxic impurity (GTI) control under the ICH M7(R2) framework, and process scaling from gram to hundred‑kilogram batches. For XDC programs, Sintaho has developed multiple linkers and linker‑payload combinations. The GMP‑compliant XDC manufacturing platform offers production services to global partners. On‑site, Sintaho held detailed discussions with multiple overseas clients covering custom development of high‑potency intermediates, payloads / linkers and conjugate‑drug collaborations.
One‑stop Full‑chain C(D)MO Services Recognized Globally for Proven Strength
Beyond the two core technology platforms, Sintaho presented its end‑to‑end C(D)MO portfolio. It spans structural modification, regulatory filing (DMF / CEP / ASMF), process scaling, commercial supply and full‑life‑cycle management (LCM), supporting both generic and innovator‑drug projects. For generics, services center on API supply and regulatory submission support. For innovative drugs, Sintaho delivers custom CDMO development and process industrialization, and clear explained its service boundaries to visitors.
LCM offerings cover post‑approval change management under the ICH Q12 established‑conditions framework, continued process verification (CPV), and responses to pharmacopoeia method revisions.
Sintaho operates approximately 55,000 m² of GMP‑compliant manufacturing space. It successfully passed FDA on‑site inspections in August 2024 and October 2025. The 2025 inspection reviewed the full quality system including facilities, materials, production, packaging & labeling and laboratory controls, earning high praise from FDA investigators. Robust quality management and proven international compliance constitute core competitive advantages attracting global customers at CPHI.
Booming On‑site Exchanges — You Are Welcome to Connect
On opening day, Sintaho’s booth welcomed a steady stream of global visitors. Sintaho’s business team engaged broad‑ranging conversations on potential partnerships for GLP‑1 peptide APIs, ADC/XDC conjugates and OEB5 high‑potency small molecules. Hot topics included generic GLP‑1 peptide API supply, and custom development for peptides, high‑potency substances and XDC payloads / linkers.
CPHI Milan 2026 runs from October 6 to 8. Sintaho remains at Booth 3K47, Hall 3.
If you are seeking C(D)MO collaboration for peptides, XDC compounds, OEB5 APIs or complex peptides, please drop by our booth for face‑to‑face meetings. You may also schedule discussions in advance via email: sales@sintaho.com or our official website: www.sintaho.com.
Let us seize new collaboration opportunities together in Milan. We look forward to meeting you on‑site!
Event Information: CPHI Worldwide 2026 | 6‑8 October 2026 | Fiera Milano, Italy | Booth 3K47
